PAN joins 85+ healthcare organizations in a letter urging CMS to expand coverage of obesity treatments under Medicare Part D and B
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
The PAN Foundation signed on to a letter from more than 85 healthcare organizations, patient advocacy groups, and medical associations to the Centers for Medicare & Medicaid Services Administrator, urging him to include access for Medicare recipients to evidence-based obesity treatments in an upcoming proposed rule.
Obesity is a treatable chronic disease that plays a major factor in many other conditions such as type 2 diabetes, hypertension, heart disease, fatty liver disease, kidney disease, lipid disorders, certain cancers, sleep apnea, arthritis, and mental illness. The treatment of obesity requires a comprehensive approach including IBT, FDA-approved obesity medications, and metabolic and bariatric surgery as determined by a health care professional.
Medicare Part D’s prohibition of coverage for “weight loss” medications is a major barrier for older Americans and those living with disabilities, and many dual eligible beneficiaries, to receiving medically necessary, safe, and effective FDA-approved pharmacotherapy to treat obesity. Medicare’s current interpretation and restriction is outdated and does not reflect the prevailing medical consensus of the disease.
Read the letter to CMS Administrator